| 引用本文: | 甄路路,薛淑一,庄雪梅,杨海.帕博利珠单抗联合仑伐替尼治疗晚期实体肿瘤的疗效和安全性的Meta分析[J].中国现代应用药学,2025,42(5):59-65. |
| zhenlulu,xueshuyi,zhuangxuemei,yanghai.Meta-analysis of the efficacy and safety of pabrolizumab combined with lenvatinib in the treatment of advanced solid tumors[J].Chin J Mod Appl Pharm(中国现代应用药学),2025,42(5):59-65. |
|
| 摘要: |
| 目的:评价帕博利珠单抗联合仑伐替尼治疗晚期实体肿瘤的疗效和安全性。方法:利用计算机检索Pubmed、EMBase、Cochrane Library、ISI Web of Science、中国知网、万方数据库和维普数据库等数据库。根据文献纳入标准和排除标准收集帕博利珠单抗联合仑伐替尼治疗晚期实体肿瘤的相关临床随机对照试验(RCT)文献，采用RevMan5.3软件进行Meta分析。结果:最终纳入5项研究，共计4493例患者，其中试验组1883例，对照组2610例。Meta分析结果显示: 帕博利珠单抗联合仑伐替尼在无进展生存期[HR=0.51，95%CI（0.51,1.29），P<0.00001]、总生存期[HR=0.63，95%CI（0.54,0.74），P<0.00001]、客观反应率[RR=1.99，95%CI（1.80,2.85），P<0.00001]和完全反应率[RR=3.11，95%CI（1.41,6.87），P=0.005]方面明显优于对照组，其差异有统计学意义。在安全性方面，Meta分析显示，帕博利珠单抗联合仑伐替尼在治疗晚期实体肿瘤时出现或恶化的3级或以上不良事件[RR=1.08，95%CI（0.90,1.08），P=0.14]上没有统计学差异。 |
| 关键词: 帕博利珠单抗 仑伐替尼 晚期实体肿瘤 疗效 不良反应 Meta 分析 |
| DOI： |
| 分类号: |
| 基金项目:青岛市临床重点专科[青岛市卫生健康委员会,编号(2022)6]。 |
|
| Meta-analysis of the efficacy and safety of pabrolizumab combined with lenvatinib in the treatment of advanced solid tumors |
|
zhenlulu, xueshuyi, zhuangxuemei, yanghai
|
|
qingdao centrol hospital
|
| Abstract: |
| Objective:To evaluate the efficacy and safety of pablizumab in combination with lenvatinib in the treatment of advanced solid tumors. Methods:Computer searches of Pubmed, EMBase, Cochrane Library, ISI Web of Science, China Knowledge Network, Wanfang database and Wipu database were used. The literature related to clinical randomized controlled trials (RCTs) of pabrolizumab in combination with lenvatinib for advanced solid tumors was collected according to the inclusion and exclusion criteria, and Meta-analysis was performed using RevMan 5.3 software. Results:Five studies with a total of 4493 patients were finally included, including 1883 patients in the trial group and 2610 patients in the control group.Meta-analysis results showed that: pabrolizumab in combination with lenvatinib was associated with progression free survival [HR=0.51, 95% CI (0.51,1.29), overall survival [HR=0.63, 95% CI ( 0.54,0.74), P<0.00001], objective response rate [RR=1.99, 95% CI (1.80,2.85), P<0.00001] and complete response rate [RR=3.11, 95% CI (1.41,6.87), P=0.005] were significantly better than those in the control group, and the differences were statistically significant. In terms of safety, Meta-analysis showed that there was no statistically significant difference in grade 3 or higher adverse events [RR=1.08, 95% CI (0.90,1.08), P=0.14] for pablizumab in combination with lenvatinib in the treatment of advanced solid tumors that developed or worsened. |
| Key words: Pabrolizumab lenvatinib advanced solid tumors efficacy adverse events Meta-analysis |
